Skip to content
Review Open access

Narrow Therapeutic Index Drugs: Regulatory Frameworks, Bioequivalence, and Model-Informed Precision Dosing

Sep 2026 · Pharmaceutics · Vol 18 · 0 citations · 105 references
Medicine

TL;DR

Greater international harmonization, standardized model validation, prospective clinical evaluation, and integration of regulatory, formulation, and patient-level data are needed to support safer substitution and more reliable precision dosing.

Abstract

Background/Objectives: Narrow therapeutic index (NTI) drugs are characterized by a small margin between effective and toxic exposure. This review aimed to summarize international definitions and regulatory frameworks for NTI drugs, compare bioequivalence requirements for generic NTI products, and evaluate the role of model-informed approaches in precision dosing and lifecycle risk management. Methods: A structured literature search was conducted in PubMed, MEDLINE, Embase, Web of Science, Scopus, and the China National Knowledge Infrastructure from database inception to 30 June 2026. Official documents from major regulatory authorities were also reviewed. Evidence relating to NTI drug classification, bioequivalence, interchangeability, therapeutic drug monitoring, population pharmacokinetics, physiologically based pharmacokinetics, machine learning, and hybrid modeling was included. Results: Definitions, drug lists, study designs, and bioequivalence criteria varied substantially across jurisdictions. Several authorities use narrowed acceptance ranges, whereas China and the United States apply fully replicated crossover designs with reference-scaled average bioequivalence, average bioequivalence constraints, and within-subject variability comparisons for selected NTI drugs. Population pharmacokinetic and Bayesian approaches remain the most mature tools for therapeutic drug monitoring and individualized dosing. Physiologically based models support drug–drug interaction prediction, special-population extrapolation, virtual bioequivalence, and clinically relevant formulation specifications. Machine-learning and hybrid models improve exposure, dose, and toxicity-risk prediction, but most evidence remains retrospective and externally limited. Conclusions: NTI drug regulation and clinical management remain heterogeneous. Greater international harmonization, standardized model validation, prospective clinical evaluation, and integration of regulatory, formulation, and patient-level data are needed to support safer substitution and more reliable precision dosing.

Read PDF

Similar papers

Review Open access Oct 2026

Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion

Biosimilar regulation was established using a systematic, stepwise framework in which clinical comparisons addressed residual uncertainties following comprehensive quality and pharmacokinetic assessments. Advances in analytical resolution, clinical pharmacology, and over two decades of regulatory expertise have substan...

S. Niazi · 0 citations
Open access 2026

The role of PK/PD modeling and in silico approaches in drug development: A pharmaceutical industry perspective

Pharmacokinetic/pharmacodynamic (PK/PD) modeling and in silico approaches have become central to modern drug development, providing a quantitative framework for evidence-based decisions across non-clinical, translational, and clinical stages. Model-informed drug development integrates approaches such as population PK/P...

B. Golubovic · 0 citations
Review Open access Nov 2026

Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development

Abstract Clinical pharmacokinetic drug–drug interaction (PK‐DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK‐DDIs, so the clinical consequences of these interactions, par...

T. Polasek, J. Miners · 0 citations
Review Oct 2026

From CYP450 pharmacogenomics to personalized medicine: clinical evidence, dosing guidelines, and future perspectives.

Interindividual variability in drug response remains a critical challenge in contemporary pharmacotherapy, and cytochrome P450 (CYP450) genetic polymorphisms are a principal determinant of this heterogeneity. The CYP450 superfamily mediates the oxidative biotransformation of 70-80% of clinically prescribed medications....

K. Aldossary, Dalia K. Zaafar, Nada A. Alsaleh et al. · 0 citations
Review Oct 2026

Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines.

INTRODUCTION Pharmacogenetics is pivotal in modern HIV management, facilitating the transition from the traditional "one-size-fits-all" model toward personalized precision medicine. By analyzing how unique genetic profiles influence pharmacological responses, clinicians can maximize therapeutic efficacy while minimizin...

Rita Nogueiras-Álvarez · 0 citations
Oct 2026

Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling.

The authors' model predicts that ceritinib co-administration substantially elevates rivaroxaban exposure and exploratory major bleeding risk, and predicts model-predicted dosing strategies comparable to standard monotherapy.

Jian-Wei Ren, Yi-Yao Li, Xin Zheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.